Therapeutic Goods (Exempt Monographs) Determination 2021

The central concept is the standard as defined in subsection 3(1) of the Therapeutic Goods Act. The definition includes references to monographs in several pharmacopoeias: the British Pharmacopoeia, the European Pharmacopoeia, and the United States Pharmacopeia-National Formulary. When a monograph is a standard, goods to which that standard applies must conform to its requirements unless an exemption applies. Failure to conform means the goods are likely to be treated as non‑standard and may be refused listing or registration, or may be subject to regulatory action. The definition is critical because the Act requires that goods on the Australian Register of Therapeutic Goods meet applicable standards. For listed goods, the sponsor certifies compliance; for registered goods, the TGA assesses compliance.

A monograph is a published standard that sets out the required specifications for a particular substance or product, including identity, purity, strength, and sometimes labelling. Pharmacopoeias are official compilations of such monographs, updated periodically. The United States Pharmacopeia-National Formulary (USP-NF) is an American compendium; the British Pharmacopoeia (BP) and European Pharmacopoeia (Ph. Eur.) are European standards. Australian law incorporates these by reference rather than reproducing them.

The instrument also relies on the concept of listed goods and export only medicines. Listed goods are lower‑risk therapeutic goods that may be entered on the Register without prior evaluation, based on a sponsor’s self‑assessment. Export only medicines are those manufactured in Australia solely for export, not for supply domestically. The Schedule 2 exemption excludes export only medicines, meaning that live microorganism products destined for overseas markets must still comply with the label statement unless the importing country’s rules differ. This is a curious carve‑out, as it may impose additional costs on Australian exporters compared to domestic suppliers. It suggests the drafter focused on domestic consumer protection or on harmonising with TGA’s own labelling requirements, rather than on reducing export burdens.

The term whole live microorganism is not defined in the determination itself, but its ordinary meaning implies a viable, intact organism. The exclusion of Arthrospira species (spirulina) means that manufacturers of spirulina products cannot rely on the exemption; they must continue to list stabilisers and excipients on the label as required by the pharmacopoeial monographs. This distinction may be because spirulina is often marketed as a food or food supplement, not a medicine, or because the TGA considers label disclosure for those products to be important for consumer safety.

Another key concept is eligible for listing. The Act defines eligibility for listing in Part 3‑2, which requires that the goods be of a kind that can be listed (e.g., not a prescription medicine, not a biological, etc.). The determination ties the exemption to this eligibility status, meaning that even if a product is not yet listed but qualifies for listing, it may still benefit from the exemption. This avoids penalising sponsors who have not yet completed the listing process.

Finally, the instrument introduces the idea of exempt monographs versus exempt parts of monographs. The latter is a more nuanced relief, where only a specific sentence or requirement within a monograph is disapplied, leaving the rest of the monograph intact. This precision reduces the risk of unintended consequences from wholesale exemptions. It also demonstrates that the Secretary (or delegate) considered the exact wording of the monograph and chose a targeted carve‑out rather than a blanket waiver.

The primary affected group is manufacturers and sponsors of therapeutic goods that fall within the scope of the exempted monographs. For Schedule 1, this includes any person or company that produces, imports, or supplies goods containing antithrombin III human, factor IX complex, pancreatin, pancrelipase, or plasma protein fraction. These are typically blood‑derived or pancreatic enzyme products used in hospitals and for specific medical conditions. The exemption removes the need to comply with the USP‑NF monograph for these substances, but manufacturers must still comply with any other applicable standards, such as the TGA’s own standards or other pharmacopoeial editions. The cost saving is modest: manufacturers no longer need to test or formulate to the USP‑NF specification for these particular substances, but they may already be using other standards (e.g., BP, Ph. Eur., or in‑house specifications). The practical effect is greatest for manufacturers who previously had to meet multiple pharmacopoeial standards for global distribution; now they can disregard the USP‑NF requirement for these substances when supplying the Australian market.

For Schedule 2, the affected group is narrower: sponsors of medicines that are listed goods (or eligible for listing) and contain a whole live microorganism as an active ingredient, excluding Arthrospira species. This covers many probiotic products, live bacterial vaccines, and yeast‑based therapies. The exemption applies only to a single label requirement: stating the name of stabilisers and excipients. The BP and Ph. Eur. monographs (specifically monograph 3053) require that the label list these components. The exemption means that sponsors of these live microorganism products do not need to disclose stabilisers and excipients on the label as a matter of pharmacopoeial compliance. However, other labelling requirements under the Act (such as those in the Therapeutic Goods Order on labelling) may still compel disclosure. The exemption thus relieves one potential source of inconsistency or duplication.

Regulators within the Therapeutic Goods Administration are also affected. They must apply the exemptions when assessing compliance or investigating complaints. If a sponsor relies on the exemption, the TGA cannot take enforcement action for breach of the exempted monograph provisions. However, the TGA may still pursue other avenues if the labelling fails to comply with other statutory requirements.

Consumers and healthcare professionals are indirectly affected. For Schedule 2 products, consumers may receive less information on labels about excipients, potentially affecting those with allergies or sensitivities to stabilisers. The exemption does not prevent a sponsor from voluntarily including the information, but it removes the legal compulsion. From a consumer protection standpoint, this is a trade‑off: reduced regulatory burden for industry versus reduced information for end users. The drafter presumably concluded that for live microorganism products, the pharmacopoeial label requirement is unduly burdensome or unnecessary, perhaps because live organisms often require special handling or because excipient disclosure is already covered by other instruments.

Exporters of live microorganism products are excluded from the Schedule 2 exemption. This means Australian manufacturers who export such products must still comply with the BP/Ph. Eur. label statement if they want to claim compliance with those pharmacopoeias for the Australian market. However, if the product is only exported and not supplied domestically, the exemption is irrelevant because the goods are not listed in Australia. The exclusion of export only medicines from the exemption may impose an additional compliance burden on exporters who wish to supply domestically as well, forcing them to maintain two labelling regimes.

This determination does not create new duties. Instead, it removes existing duties that would otherwise arise from the definition of standard. Before the determination, any therapeutic good to which a USP‑NF monograph applied was required to conform to that monograph. After the determination, goods listed in Schedule 1 are not required to conform to the specified monographs. The key right conferred is the right to disregard those specific monograph provisions without risking non‑compliance with the Act. However, this right is conditional: the goods must match exactly the description in Column 4 of the schedules. If a manufacturer produces a different batch of plasma protein fraction that is not covered by the item, the right does not extend.

For Schedule 2, the right is even more limited: sponsors may choose not to include the label statement about stabilisers and excipients as required by BP/Ph. Eur. monograph 3053. But they still have a duty to comply with the rest of that monograph, and with all other applicable standards. The instrument does not absolve them of any other labelling duty under the Therapeutic Goods Order No. 91 or other regulations. Therefore, a sponsor who omits the excipient list relying solely on this exemption should verify that no other law requires that information. Failure to do so could lead to enforcement action despite the exemption.

There is no duty under this instrument to notify the TGA that a sponsor is relying on an exemption. The exemption applies automatically to the described goods. However, during an audit or listing application, the TGA may ask the sponsor to justify why certain monograph requirements were not followed. In practice, sponsors should keep records demonstrating that their product falls within the exempted category.

The instrument also creates a right for the Secretary to later vary or revoke the exemptions under section 33(3) of the Acts Interpretation Act 1901 (as applied to legislative instruments). This means the exemption is not permanent. If the TGA later determines that the exemption is no longer appropriate (e.g., due to safety concerns or international harmonisation), the instrument could be amended, and sponsors would then need to comply with the formerly exempted provisions. This regulatory uncertainty imposes a risk: a sponsor who currently benefits from the exemption may have to redesign its product or labelling if the exemption is withdrawn. There is no grandfathering or transition period explicitly provided in this instrument.

For competitors whose products are not covered by the exemption, there is a right to seek judicial review if they consider the determination to be ultra vires or procedurally defective. The instrument is subject to disallowance and can be challenged in the Federal Court. The narrower the exemption, the more likely it is to survive a challenge.

The instrument itself does not create any penalties. Penalties for failing to comply with standards arise under the Therapeutic Goods Act. For example, section 22(5) of the Act makes it an offence to supply therapeutic goods that do not comply with applicable standards, with maximum penalties ranging from 500 penalty units for an individual to 2,500 penalty units for a body corporate, plus possible imprisonment for serious offences. Civil penalties also apply under Part 4‑2 of the Act.

Because the exempted monographs are no longer standards for the specified goods, non‑compliance with those specific provisions cannot form the basis of a prosecution or civil penalty for breach of a standard. This is the enforcement consequence of the determination. However, a manufacturer who mistakenly believes that their product is covered by the exemption when it is not could still face enforcement action. For example, if a manufacturer of a live microorganism product includes Arthrospira platensis as an active ingredient, the exemption does not apply, and the label must comply with the BP/Ph. Eur. statement. If the manufacturer omits the excipient information, they may be prosecuted for supplying goods that do not comply with the applicable standard.

The TGA’s enforcement powers are not diminished by this instrument. The TGA can still issue infringement notices, seek injunctions, or pursue criminal prosecution for violations of other standards. The instrument simply narrows the definition of standard for a specific set of circumstances. If the TGA finds that a sponsor has deliberately misinterpreted the scope of the exemption, it may take enforcement action for non‑compliance with the Act’s general obligations, such as the requirement that listed goods be of an acceptable quality and safe for use. The exemption does not provide immunity from those broader duties.

There is also the possibility of private enforcement by competitors under the Competition and Consumer Act 2010 if the exemption leads to misleading or deceptive conduct. For example, if a probiotic product omits the excipient list and consumers are misled about its composition, a competitor or consumer could bring an action. However, the determination itself is not a defence to such claims; it only addresses compliance with the pharmacopoeial standard.

Given the narrow scope of the exemption, the practical enforcement risk is low for most sponsors. The main risk is inadvertent misinterpretation of the eligibility criteria, particularly for Schedule 2 where the product must be eligible for listing (not just listed) and must contain a whole live microorganism (not a dead one or a component). Manufacturers of probiotics should carefully document the viability of their organism and the filing status of their listing application.

This determination operates within the framework of the Therapeutic Goods Act 1989 and its regulations. It is a legislative instrument made under section 3C, which grants the power to exempt monographs from the definition of standard. It does not amend any other provision of the Act, but it does affect how other provisions operate. For example, section 26 of the Act requires that listed goods comply with applicable standards. Because the exempted monographs are no longer applicable standards for the specified goods, section 26 does not require compliance with them. However, the goods must still comply with any other applicable standards, such as those in the British Pharmacopoeia or European Pharmacopoeia that have not been exempted.

The determination interacts with the Therapeutic Goods Order No. 91 on labelling. That order contains its own requirements for the disclosure of excipients. For live microorganism products, if the TGO 91 requires the name of stabilisers and excipients to be stated on the label, then the exemption from the pharmacopoeial statement does not relieve the sponsor of that requirement. The sponsor must satisfy both the exemption and the TGO; the exemption simply removes one potential source of inconsistency. Sponsors should treat the determination as a minimum compliance floor, not a ceiling.

The Therapeutic Goods Regulations 1990 also reference standards. Regulation 6 prescribes certain goods as not being medicinal products, which affects listing eligibility. This determination does not alter the regulations; it only adjusts the definition of standard used in interpreting those regulations.

For export only medicines, the interaction is more complex. The Schedule 2 exemption explicitly excludes export only medicines. This means that a live microorganism product made solely for export must comply with the full BP/Ph. Eur. monograph, including the label statement, even if the importing country does not require it. This may impose a cost on Australian exporters that domestic suppliers do not face. However, if the product is also intended for the domestic market, it qualifies as a listed good (or eligible for listing) and the exemption applies, provided it is not an export only medicine. The distinction between export only and domestically supplied goods is therefore critical.

The determination may also interact with state and territory legislation on medicines, but those provisions are typically overridden by the Commonwealth Act. State poisons schedules and labelling laws are not affected by this Commonwealth instrument; state law may still require disclosure of excipients for safety reasons. The determination does not purport to exempt from state law.

Finally, the instrument interacts with international trade obligations. By exempting certain USP-NF monographs, Australia may be seen to be departing from internationally recognised standards, which could affect mutual recognition agreements or trade negotiations. However, the exemption is narrow and likely of limited trade significance.

The instrument as provided is titled Therapeutic Goods (Exempt Monographs) Determination 2021. The text does not include any amendment history within its provisions. It is the original version, made in 2021. Legislative instruments made under section 3C are often updated periodically as new pharmacopoeial editions are published or as the TGA revises its exemptions. Practitioners should check the Federal Register of Legislation for any subsequent amending instruments. For instance, the 2021 determination may have been replaced or amended by later determinations, such as the 2022 or 2023 versions. Without the amendment history explicitly recited, we cannot assume it remains current.

The power to make such determinations has existed since the Therapeutic Goods Amendment Act 2018 inserted section 3C into the Act. The 2021 determination is therefore one of a series. Earlier determinations might have covered different monographs. The explanatory statement for this instrument (if available) would indicate whether it replaced an earlier determination or whether it was the first of its kind.

Because the instrument does not list its own amendments, analysts must rely on external sources. The absence of amendment history in the document does not mean none exist; it simply means the document is a standalone instrument. To provide accurate advice, a practitioner would need to confirm whether this is the current version. This uncertainty itself is a compliance cost: users must invest time to verify the instrument’s status.

If the determination has been amended, the exemptions may have expanded or contracted. For example, additional monographs might have been added to Schedule 1, or the scope of Schedule 2 might have been broadened to include other microorganisms. Conversely, amendments could have removed exemptions if the TGA reconsidered the policy. The instrument contains no sunset clause, so it remains in force until repealed.

Given the specificity of the exemptions, any amendment would likely be motivated by industry requests or by changes to the pharmacopoeias themselves. For instance, if the USP-NF updates the monographs for antithrombin III or pancrelipase, the TGA may decide that the exemption is no longer appropriate and remove it. Sponsors relying on these exemptions should monitor the TGA’s website for proposed changes.

The instrument itself contains no references to litigation. No court cases are cited, and the text does not mention any judicial challenge. This is unsurprising for a narrow, technical legislative instrument that is unlikely to attract litigation. However, that does not mean no cases exist. A search of the Federal Court and Administrative Appeals Tribunal records would be needed to determine whether the determination or its predecessor has been judicially considered.

Possible grounds for a challenge could include ultra vires (if the determination exceeds the power under section 3C), procedural error (if the consultation or disallowance process was flawed), or inconsistency with the Act’s objects. Given that the exemption is permissive (it removes a requirement), a third party (such as a competitor) might argue that the exemption undermines consumer safety or creates an unfair competitive advantage. Alternatively, a sponsor who was denied an exemption for their product might challenge the determination as unreasonable or discriminatory.

The instrument is a disallowable legislative instrument, which means it can be debated and potentially disallowed by Parliament. That political process is more likely than litigation, but disallowance is rare for technical instruments. Nonetheless, the instrument’s validity depends on it being properly tabled and not disallowed.

Should litigation arise, the court would interpret the instrument strictly according to its text, given that it grants an exemption from a generally applicable definition. Ambiguities would likely be resolved against the exemption, following the principle that exemptions are construed narrowly. For example, if there is doubt as to whether a particular live microorganism product qualifies under Schedule 2, the court would likely require clear evidence that the product falls within the words.

For now, the instrument has a clean litigation history as far as the source reveals. Analysts should treat it as currently effective but subject to potential future challenge.

Several traps exist for the unwary. First, the Schedule 1 exemption covers therapeutic goods broadly, but only for the specific monographs listed. A manufacturer using a different USP-NF monograph for a related substance (e.g., factor VIII instead of factor IX complex) cannot rely on the exemption. The items are specific; column 2 names exact monograph titles. Any substitution or variant is not covered.

Second, the Schedule 2 exemption applies only to the statement in monograph 3053 that the label states the name of any stabilisers and other excipients. It does not exempt any other statements in that monograph, such as requirements for identity testing, purity, or potency. A sponsor who disregards the entire monograph thinking it is exempt would be in breach.

Third, the eligibility condition for Schedule 2 requires that the medicine contain a whole live microorganism as an active ingredient. If the microorganism is killed or is a component (e.g., a cellular extract), the exemption does not apply. Probiotic products that are heat‑treated or formulated with dead bacteria are not covered. Additionally, the exclusion of Arthrospira maxima and Arthrospira platensis is absolute. A product containing spirulina cannot claim the exemption even if it contains other live bacteria.

Fourth, the medicine must be listed goods or eligible for listing, other than export only medicines. This excludes goods that are solely for export, even if they contain live microorganisms. It also excludes goods that are not eligible for listing, such as prescription medicines or biologicals that require registration. A sponsor who intends to register a live microbial product as a prescription medicine cannot use the exemption unless it is also eligible for listing (unlikely). The exemption is therefore limited to low‑risk products suitable for the listed goods pathway.

Fifth, the exemption does not override the Therapeutic Goods Order No. 91 or other labelling requirements. Even if the pharmacopoeial statement is exempt, the TGO may still require the same or similar information. Sponsors must comply with the most onerous applicable requirement. Relying solely on the determination may lead to non‑compliance with the TGO.

Sixth, the determination does not provide guidance on what constitutes a whole live microorganism. Does a consortium of bacteria count? What about spores? Courts would likely rely on ordinary scientific meaning, but uncertainty could arise. Sponsors should obtain expert microbiological advice and document their reasoning.

Finally, the instrument is a legislative instrument, not a guideline. It has binding legal effect. Sponsors should treat it with the same seriousness as the Act itself. Ignorance of the precise scope of the exemption is not a defence. If the TGA determines that a product falls outside the exemption, the sponsor may face enforcement action for failing to comply with the non‑exempted monograph.

Compliance begins with identification. A manufacturer or sponsor should first determine whether their therapeutic good falls within the scope of either schedule. For Schedule 1, check if the good contains one of the five listed substances (antithrombin III human, factor IX complex, pancreatin, pancrelipase, or plasma protein fraction) and whether the relevant USP-NF monograph is the one specified. If so, the full monograph is exempt. The sponsor does not need to take any further action regarding that monograph for Australian regulatory purposes. However, they should still retain records demonstrating that the good contains that substance, in case the TGA audits.

For Schedule 2, compliance is more nuanced. The sponsor must confirm that:

• The medicine is a listed good or is eligible for listing.
• It is not an export only medicine.
• It contains a whole live microorganism as an active ingredient (other than Arthrospira species).
• The microorganism is alive and whole (not a lysate or extract).

If all conditions are satisfied, the sponsor may choose not to include the label statement required by monograph 3053 in the BP and Ph. Eur. regarding stabilisers and excipients. However, they should still include that information if required by the TGO No. 91 or any other applicable standard. To be safe, the sponsor should conduct a cross‑check of all labelling requirements. The best practice is to include the excipient list voluntarily, as it rarely imposes significant cost and avoids any risk of non‑compliance with other instruments.

The sponsor should document their reasoning for relying on the exemption. This includes retaining a copy of the determination, the relevant pharmacopoeial monograph, and evidence that the product meets the eligibility criteria (e.g., listing application details, microbiological viability test results). This documentation will be valuable during a TGA inspection.

If the product does not meet all conditions, the sponsor must comply with the full monograph. For example, a live microorganism product that is both listed and exported cannot rely on the exemption; the sponsor must choose either to modify the label for the Australian market (if the product is supplied domestically) or to ensure the export only version complies with the monograph. If the product is exported only and not supplied domestically, the exemption does not apply at all. The sponsor should then ensure the label meets the BP or Ph. Eur. requirement.

Sponsors should also monitor for amendments to this determination. If the exemption is later narrowed or revoked, they must adjust their labelling or manufacturing accordingly. Subscribing to the TGA’s consultation and notification services is advisable.

Finally, if there is any doubt about whether the good qualifies, the sponsor should seek legal advice or apply for a formal determination or guidance from the TGA. Relying on a self‑assessment of the exemption carries risk, particularly given the narrow wording and the potential for downstream enforcement action. The cost of legal review is modest compared to the potential penalties for supplying non‑standard goods.